journal article·2024-01

NIR-II responsive Janus nanoparticles amplify immunogenic cell death for enhanced cancer immunotherapy

BeiBei Chen, KangLi Guo, HaoRan Wang, Fu-Jian Xu, JuLin Wang, NaNa Zhao

Publisher page

Abstract

Immunotherapy brings new hope for tumor treatment by inducing immunogenic cell death (ICD) of tumor cells. However, insufficient immunogenicity and low immune response rate greatly limit antitumor immunity. Herein, by optimizing the composition and morphology, the rational design of Janus nanoparticles composed of Fe3O4 nanospheres and SiO2 nanorods was realized for enhanced cancer immunotherapy through amplified ICD. After glucose oxidase (GOx) was loaded by the Janus nanoparticles, the resultant M-FS-GOx consumes glucose at tumor sites to generate gluconic acid and hydrogen peroxide (H2O2) for starvation therapy while the H2O2 supply promotes the production of highly toxic ·OH to achieve effective chemodynamic therapy (CDT). Under a 1064 nm light irradiation, the photothermal effect of M-FS-GOx enhances the enzyme activity of GOx for improved starvation therapy. Furthermore, both tumor-associated antigens released during the process of ICD and the intrinsic immunoadjuvant property of M-FS-GOx stimulate dendritic cell maturation to activate antitumor immune responses. This work provides a promising strategy for the construction of Janus nanoparticles to achieve enhanced cancer immunotherapy through combination therapy-amplified ICD.
Source: expertdata · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. Waldman A D, Fritz J M, Lenardo M J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol, 2020, 20: 651–66810.1038/s41577-020-0306-5 ↗
2. Goldberg M S. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer, 2019, 19: 587–60210.1038/s41568-019-0186-9 ↗
3. Duan X, Chan C, Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed, 2019, 58: 670–68010.1002/anie.201804882 ↗
4. Guo K, Jiao Z, Zhao X, et al. Melanin-based immunoregulatory nanohybrids enhance antitumor immune responses in breast cancer mouse model. ACS Nano, 2023, 17: 10792–1080510.1021/acsnano.3c02287 ↗
5. Wan J, Zhang X, Tang D, et al. Biodegradable NIR-II pseudo conjugate polymeric nanoparticles amplify photodynamic immunotherapy via alleviation of tumor hypoxia and tumor-associated macrophage reprogramming. Adv Mater, 2023, 35: 220979910.1002/adma.202209799 ↗
6. Chen H L, Liu H, Liu L X, et al. Fabrication of subunit nanovaccines by physical interaction. Sci China Tech Sci, 2022, 65: 989–99910.1007/s11431-021-2011-7 ↗
7. Bai Y T, Wang T R, Zhang S L, et al. Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. Sci China Tech Sci, 2022, 65: 1011–102810.1007/s11431-021-1961-y ↗
8. Zhao X, Guo K, Zhang K, et al. Orchestrated yolk-shell nanohybrids regulate macrophage polarization and dendritic cell maturation for oncotherapy with augmented antitumor immunity. Adv Mater, 2022, 34: 210826310.1002/adma.202108263 ↗
9. Chang M, Wang M, Wang M, et al. A multifunctional cascade bioreactor based on hollow-structured Cu2MoS4 for synergetic cancer chemo-dynamic therapy/starvation therapy/phototherapy/immunotherapy with remarkably enhanced efficacy. Adv Mater, 2019, 31: 190527110.1002/adma.201905271 ↗
10. Tang Y, Bisoyi H K, Chen X M, et al. Pyroptosis-mediated synergistic photodynamic and photothermal immunotherapy enabled by a tumor-membrane-targeted photosensitive dimer. Adv Mater, 2023, 35: 230023210.1002/adma.202300232 ↗
11. Zhao Q, Liang G, Guo B, et al. Polyphotosensitizer-based nanoparticles with Michael addition acceptors inhibiting GST activity and cisplatin deactivation for enhanced chemotherapy and photodynamic immunotherapy. Adv Sci, 2023, 10: 230017510.1002/advs.202300175 ↗
12. Li W, Jiang Y, Lu J. Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy. Int J Pharm, 2023, 634: 12265510.1016/j.ijpharm.2023.122655 ↗
13. Zhao N, Yan L, Xue J, et al. Degradable one-dimensional dextran-iron oxide nanohybrids for MRI-guided synergistic gene/photothermal/magnetolytic therapy. Nano Today, 2021, 38: 10111810.1016/j.nantod.2021.101118 ↗
14. Huang X, Teng X, Chen D, et al. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials, 2010, 31: 438–44810.1016/j.biomaterials.2009.09.060 ↗
15. Huang Z, Yao D, Ye Q, et al. Zoledronic acid-gadolinium coordination polymer nanorods for improved tumor radioimmunotherapy by synergetically inducing immunogenic cell death and reprogramming the immunosuppressive microenvironment. ACS Nano, 2021, 15: 8450–846510.1021/acsnano.0c10764 ↗
16. Song Z, Fang J, Wang Z, et al. Rod-shaped polymeric nanoparticles intervene neutrophils for efficient ischemic stroke therapy. Adv Funct Mater, 2023, 33: 221232610.1002/adfm.202212326 ↗
17. Zhang X, Fu Q, Duan H, et al. Janus nanoparticles: From fabrication to (bio)applications. ACS Nano, 2021, 15: 6147–619110.1021/acsnano.1c01146 ↗
18. Zhang Y, Huang K, Lin J, et al. Janus nanoparticles in cancer diagnosis, therapy and theranostics. Biomater Sci, 2019, 7: 1262–127510.1039/C8BM01523F ↗
19. Wang Z, Zhang F, Shao D, et al. Janus nanobullets combine photodynamic therapy and magnetic hyperthermia to potentiate synergetic anti-metastatic immunotherapy. Adv Sci, 2019, 6: 190169010.1002/advs.201901690 ↗
20. Pham T C, Nguyen V N, Choi Y, et al. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy. Chem Rev, 2021, 121: 13454–1361910.1021/acs.chemrev.1c00381 ↗
21. Xu C, Pu K. Second near-infrared photothermal materials for combinational nanotheranostics. Chem Soc Rev, 2021, 50: 1111–113710.1039/D0CS00664E ↗
22. Zhao P, Li H, Bu W. A forward vision for chemodynamic therapy: Issues and opportunities. Angew Chem Int Ed, 2023, 62: e20221041510.1002/anie.202210415 ↗
23. Tang Z, Liu Y, He M, et al. Chemodynamic therapy: Tumour microenvironment-mediated fenton and fenton-like reactions. Angew Chem, 2019, 131: 958–96810.1002/ange.201805664 ↗
24. Gao S, Lin H, Zhang H, et al. Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction. Adv Sci, 2019, 6: 180173310.1002/advs.201801733 ↗
25. Feng W, Han X, Wang R, et al. Nanocatalysts-augmented and photothermal-enhanced tumor-specific sequential nanocatalytic therapy in both NIR-I and NIR-II biowindows. Adv Mater, 2019, 31: 180591910.1002/adma.201805919 ↗
26. Li C, Wan Y, Zhang Y, et al. In situ sprayed starvation/chemodynamic therapeutic gel for post-surgical treatment of iDH1 (R132H) glioma. Adv Mater, 2022, 34: 210398010.1002/adma.202103980 ↗
27. Fang C, Deng Z, Cao G, et al. Co-ferrocene MOF/glucose oxidase as cascade nanozyme for effective tumor therapy. Adv Funct Mater, 2020, 30: 191008510.1002/adfm.201910085 ↗
28. Hu J J, Liu M D, Gao F, et al. Photo-controlled liquid metal nanoparticle-enzyme for starvation/photothermal therapy of tumor by win-win cooperation. Biomaterials, 2019, 217: 11930310.1016/j.biomaterials.2019.119303 ↗
29. Hao Y, Dong Z, Chen M, et al. Near-infrared light and glucose dual-responsive cascading hydroxyl radical generation for in situ gelation and effective breast cancer treatment. Biomaterials, 2020, 228: 11956810.1016/j.biomaterials.2019.119568 ↗
30. Zhou Y, Fan S, Feng L, et al. Manipulating intratumoral fenton chemistry for enhanced chemodynamic and chemodynamic-synergized multimodal therapy. Adv Mater, 2021, 33: 210422310.1002/adma.202104223 ↗
31. She D, Peng S, Liu L, et al. Biomimic FeS2 nanodrug with hypothermal photothermal effect by clinical approved NIR-II light for augmented chemodynamic therapy. Chem Eng J, 2020, 400: 12593310.1016/j.cej.2020.125933 ↗
32. Ren H, Yong J, Yang Q, et al. Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy. Acta Pharm Sin B, 2021, 11: 3244–326110.1016/j.apsb.2021.05.005 ↗
33. Zhang Y, Yang Y, Shi J, et al. A multimodal strategy of Fe3O4@ZIF-8/GOx@MnO2 hybrid nanozyme via TME modulation for tumor therapy. Nanoscale, 2021, 13: 16571–1658810.1039/D1NR04196G ↗
34. Hu Y, Mignani S, Majoral J P, et al. Construction of iron oxide nanoparticle-based hybrid platforms for tumor imaging and therapy. Chem Soc Rev, 2018, 47: 1874–190010.1039/C7CS00657H ↗
35. Gu Z, Liu T, Tang J, et al. Mechanism of iron oxide-induced macrophage activation: The impact of composition and the underlying signaling pathway. J Am Chem Soc, 2019, 141: 6122–612610.1021/jacs.8b10904 ↗
36. Meng J, Zhang P, Chen Q, et al. Two-pronged intracellular co-delivery of antigen and adjuvant for synergistic cancer immunotherapy. Adv Mater, 2022, 34: 220216810.1002/adma.202202168 ↗
37. Hong X, Zhong X, Du G, et al. The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency. Sci Adv, 2020, 6: eaaz446210.1126/sciadv.aaz4462 ↗
38. Zhang L, Zhang F, Dong W F, et al. Magnetic-mesoporous Janus nanoparticles. Chem Commun, 2011, 47: 1225–122710.1039/C0CC03946B ↗
39. Zhang M K, Li C X, Wang S B, et al. Tumor starvation induced spatiotemporal control over chemotherapy for synergistic therapy. Small, 2018, 14: 180360210.1002/smll.201803602 ↗
40. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med, 1992, 176: 1693–170210.1084/jem.176.6.1693 ↗
41. Wang R, Zhao N, Xu F J. Hollow nanostars with photothermal gold caps and their controlled surface functionalization for complementary therapies. Adv Funct Mater, 2017, 27: 170025610.1002/adfm.201700256 ↗
42. Zhao N, Fan W, Zhao X, et al. Polycation-carbon nanohybrids with superior rough hollow morphology for the NIR-II responsive multimodal therapy. ACS Appl Mater Interfaces, 2020, 12: 11341–1135210.1021/acsami.9b22373 ↗
43. Sousa de Almeida M, Susnik E, Drasler B, et al. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev, 2021, 50: 5397–543410.1039/D0CS01127D ↗
44. Fu L H, Qi C, Lin J, et al. Catalytic chemistry of glucose oxidase in cancer diagnosis and treatment. Chem Soc Rev, 2018, 47: 6454–647210.1039/C7CS00891K ↗
45. Guo Y, Jia H R, Zhang X, et al. A glucose/oxygen-exhausting nanoreactor for starvation- and hypoxia-activated sustainable and cascade chemo-chemodynamic therapy. Small, 2020, 16: 200089710.1002/smll.202000897 ↗
46. Wculek S K, Cueto F J, Mujal A M, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol, 2020, 20: 7–2410.1038/s41577-019-0210-z ↗
47. Abbaraju P L, Meka A K, Song H, et al. Asymmetric silica nanoparticles with tunable head-tail structures enhance hemocompatibility and maturation of immune cells. J Am Chem Soc, 2017, 139: 6321–632810.1021/jacs.6b12622 ↗
48. Liu X Z, Wen Z J, Li Y M, et al. Bioengineered bacterial membrane vesicles with multifunctional nanoparticles as a versatile platform for cancer immunotherapy. ACS Appl Mater Interfaces, 2023, 15: 3744–375910.1021/acsami.2c18244 ↗